Personalized mRNA vaccine shows promise in reducing melanoma return: Research
Summary
A personalized mRNA vaccine made by Moderna and Merck may help lower the chance of melanoma coming back after treatment. Researchers found this after following patients for five years in a clinical trial.Key Facts
- The vaccine is personalized, meaning it is tailored to each patient’s tumor.
- It uses mRNA technology, which helps the body’s immune system fight cancer cells.
- The study was a Phase 2b clinical trial, an advanced stage to test effectiveness and safety.
- Results came from tracking patients for five years after receiving the vaccine.
- Melanoma is the deadliest type of skin cancer.
- The vaccine aims to reduce cancer recurrence, meaning melanoma does not return after treatment.
- Moderna and Merck developed the vaccine together.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.